United States — Food and Drug Administration & Knight Therapeutics
3 shared events · Importance 6 · Last updated Apr 21, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration expressed concerns to Knight Therapeutics about the adequacy of its clinical development program for relacorilant, which is a key factor in the lawsuit against Knight Therapeutics.
Knight Therapeutics: Knight Therapeutics is facing a federal securities lawsuit for allegedly failing to disclose concerns from the FDA regarding its drug candidate, relacorilant, which could lead to a rejection of its New Drug Application. This event negatively impacts its stock price and reputation.
Jun 17, 2026 · 6 articles
Business
United States — Food and Drug Administration: The FDA approved WYNZORA in the US in 2020, but is not directly involved in the Canadian launch.
Knight Therapeutics: Knight Therapeutics is the primary actor, launching WYNZORA in Canada, which expands its product portfolio and may drive revenue growth.
Aug 20, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — Food and Drug Administration and Knight Therapeutics interact across events, view sentiment trends, and discover connected entities.
Open Dashboard